British Journal of Pharmacology

E., Tiffon, C.; E., Adams, J.; L., van der Fits,; Shijun, Wen,; A., Townsend, P.; A., Ganesan,; E., Hodges,; H., Vermeer, M.; Graham, Packham,

doi:10.1111/(issn)1476-5381

paratextBritish Journal of PharmacologyAug 4, 2010GREEN OA

British Journal of Pharmacology

TCTiffon, C. E.AJAdams, J. E.VDvan der Fits, L.WSWen, ShijunTPTownsend, P. A.

Indexed incrossref

Abstract

BACKGROUND AND PURPOSE: Vorinostat and romidepsin are histone deacetylase inhibitors (HDI), approved for the treatment of cutaneous T-cell lymphoma (CTCL). However, the mechanism(s) by which these drugs exert their anti-cancer effects are not fully understood. Since CTCL is associated with immune dysregulation, we investigated whether these HDI modulated cytokine expression in CTCL cells. EXPERIMENTAL APPROACH: CTCL cell lines and primary CTCL cells were treated in vitro with vorinostat or romidepsin, or with STAT3 pathway inhibitors. Cell cycle parameters and apoptosis were analysed by propidium iodide and annexin V/propidium iodide staining respectively. Cytokine expression was analysed using QRT-PCR and…

Citation impact

925

total citations

FWCI: —
Percentile: —
References: 0

Citations per year

Authors

9

TC
Tiffon, C. E.Corresponding
AJ
Adams, J. E.
VD
van der Fits, L.
WS
Wen, Shijun
TP
Townsend, P. A.

Topics & keywords

Topics

Estrogen and related hormone effects8%

Keywords

Pharmacology
Medicine

No related works found for this paper.